MyHep All (Sofosbuvir & Velpatasvir)

MyHep All (Sofosbuvir & Velpatasvir): Uses, Dosage, Side Effects & Complete Guide

Hepatitis C is one of those silent diseases — it can live in your body for years without showing obvious symptoms, quietly damaging your liver the whole time. The good news? It is now one of the most curable chronic viral infections in the world, thanks to modern antiviral medications. And MyHep All (Sofosbuvir & Velpatasvir) is right at the forefront of that medical breakthrough.

If you or someone you care about has been diagnosed with Hepatitis C, this guide is for you. We’re going to walk through everything — what MyHep All is, how it works, who should take it, what to expect, and what precautions to keep in mind — all in plain, easy-to-understand language.

What Is MyHep All (Sofosbuvir & Velpatasvir)?

MyHep All is a fixed-dose combination antiviral tablet that contains two powerful active ingredients:

• Sofosbuvir 400 mg
• Velpatasvir 100 mg

Together, they form a pan-genotypic direct-acting antiviral (DAA) treatment for chronic Hepatitis C virus (HCV) infection. The term “pan-genotypic” is important — it means MyHep All works against all 6 major genotypes of the Hepatitis C virus, making it a truly universal treatment option.

MyHep All is manufactured by Mylan Pharmaceuticals (now Viatris) and is widely available as a generic equivalent of the brand-name drug Epclusa. It is taken as one tablet once daily for 12 weeks in most patients — a remarkably simple and effective treatment course.

Understanding the Two Active Ingredients

Sofosbuvir — The NS5B Polymerase Inhibitor

Sofosbuvir is a nucleotide analogue inhibitor that targets the NS5B RNA-dependent RNA polymerase enzyme — a critical enzyme that the Hepatitis C virus uses to replicate its genetic material. By blocking this enzyme, Sofosbuvir essentially stops the virus from making copies of itself.

Sofosbuvir is a well-established antiviral agent that has been the backbone of Hepatitis C treatment for over a decade. It has an excellent safety profile and a high genetic barrier to resistance, meaning the virus finds it very difficult to mutate around it.

Velpatasvir — The NS5A Inhibitor

Velpatasvir targets a different part of the virus — the NS5A protein, which plays multiple roles in the HCV replication cycle, including viral assembly and release. By blocking NS5A, Velpatasvir disrupts the virus at a completely different stage of its life cycle.

The combination of Sofosbuvir and Velpatasvir creates a dual-pronged attack on the Hepatitis C virus — hitting it at two separate and essential points simultaneously. This is why the combination is so powerful and why resistance is extremely unlikely to develop.

What Is MyHep All Used For?

1. Chronic Hepatitis C — All Genotypes (1–6)

This is the primary and most important use of MyHep All (Sofosbuvir & Velpatasvir). It is approved and highly effective for treating chronic HCV infection across all six genotypes:

• Genotype 1 (most common globally, especially in North America and Europe)
• Genotype 2
• Genotype 3 (common in South Asia, including India and Pakistan)
• Genotype 4 (common in the Middle East and Africa)
• Genotype 5
• Genotype 6 (common in Southeast Asia)

This pan-genotypic coverage means that patients often do not need to know their specific HCV genotype before starting treatment — a major practical advantage, especially in settings where genotype testing is limited or expensive.

2. Patients With or Without Cirrhosis

MyHep All is effective in:

• Non-cirrhotic patients — those with chronic HCV but no liver scarring
• Patients with compensated cirrhosis (Child-Pugh Class A) — those with liver scarring but whose liver is still functioning reasonably well

⚠️ For patients with decompensated cirrhosis (Child-Pugh Class B or C), MyHep All is used in combination with Ribavirin under close medical supervision.

3. HCV/HIV Co-Infected Patients

MyHep All is also used in patients who are co-infected with both Hepatitis C and HIV, provided that potential drug interactions are carefully managed by their physician.

4. Post-Liver Transplant Patients

Patients who have undergone liver transplantation and have recurrent HCV infection can also be treated with MyHep All, though drug interaction monitoring with transplant medications is essential.

How Does MyHep All Work?

Think of the Hepatitis C virus as a factory that constantly produces copies of itself inside your liver cells. To keep producing, that factory needs specific machinery — and two of the most critical pieces of machinery are the NS5B polymerase and the NS5A protein.

• Sofosbuvir shuts down the NS5B copying machine — the virus can no longer duplicate its RNA
• Velpatasvir dismantles the NS5A assembly line — the virus can no longer properly assemble new particles

With both essential systems disabled simultaneously, the Hepatitis C virus cannot replicate, cannot assemble, and cannot spread to new liver cells. The existing virus gradually clears from the body, and your liver gets the chance to begin healing.

The ultimate goal? Achieving SVR12 — Sustained Virologic Response at 12 weeks after treatment completion. When SVR12 is achieved, the virus is undetectable in your blood for 12 weeks after finishing treatment — and this is considered a functional cure of Hepatitis C.

Clinical trials have shown that MyHep All (Sofosbuvir & Velpatasvir) achieves SVR12 rates of 95% to 99% across genotypes in non-cirrhotic patients. That is an extraordinary cure rate for any chronic viral infection.

MyHep All Dosage: How to Take It

One of the most patient-friendly aspects of MyHep All is how simple the dosing is.

Standard Adult Dose:

1 tablet (Sofosbuvir 400 mg / Velpatasvir 100 mg) once daily for 12 weeks

That’s it. One tablet a day for 3 months.

Special Dosing Scenarios:

How to Take MyHep All Correctly:

• Take with or without food — both are acceptable
• Take at the same time every day — consistency helps maintain steady drug levels
• Swallow the tablet whole with water — do not crush or split
• Do not miss a dose — if you miss one, take it as soon as you remember on the same day; if it’s the next day, skip and continue normally
• Complete the full 12-week course even if you feel better early — stopping early significantly reduces your chance of cure

What Results Can You Expect?

Here is a realistic timeline of what happens during and after MyHep All treatment:

Week 1–2: The drug begins working immediately. Viral load starts dropping significantly within the first 1–2 weeks.

Week 4: Most patients have a dramatic reduction in HCV RNA levels — many already show very low or undetectable viral load at week 4.

Week 12 (End of Treatment): The vast majority of patients have undetectable HCV RNA.

12 Weeks After Treatment (SVR12): This is the key milestone. If HCV RNA remains undetectable 12 weeks after finishing treatment, you have achieved SVR12 — a functional cure. The probability of the virus returning after SVR12 is extremely low (less than 1–2%).

Long-Term: Liver inflammation reduces. Liver enzymes normalize. In patients with early-stage fibrosis, the liver can begin to reverse some scarring. Risk of liver cirrhosis and hepatocellular carcinoma (liver cancer) drops significantly.

Common Side Effects of MyHep All (Sofosbuvir & Velpatasvir)

One of the biggest advantages of MyHep All over older Hepatitis C treatments (like Interferon-based therapy) is its significantly better tolerability. Most patients complete the full course with minimal discomfort.

Mild & Common Side Effects:

• Headache — most frequently reported
• Fatigue or tiredness — generally mild
• Nausea
• Diarrhea
• Insomnia or sleep disturbances
• Irritability or mood changes
• Weakness (asthenia)
• Back pain
• Skin rash (mild)

These side effects are typically mild and short-lived, and most patients manage them without needing any additional medication.

Side Effects When Used With Ribavirin:

If your doctor has prescribed MyHep All along with Ribavirin (for decompensated cirrhosis or certain Genotype 3 cases), you may experience more pronounced side effects, since Ribavirin itself causes additional effects such as:

• Anemia (low red blood cell count) — the most common Ribavirin-related issue
• Fatigue and shortness of breath
• Skin rash or itching
• Mood changes
• Birth defects risk (Ribavirin is strictly contraindicated in pregnancy)

Serious Side Effects (Rare — Seek Medical Attention):

• Severe bradycardia (slowed heart rate) — especially if taken with the heart medication Amiodarone (this combination is contraindicated)
• Hepatitis B reactivation — if you have hidden (occult) Hepatitis B infection, HCV treatment can trigger HBV reactivation; screening before treatment is essential
• Severe allergic reactions — rash with blistering, difficulty breathing, swelling of face or throat

⚠️ Always inform your doctor of all medications you are taking before starting MyHep All.

Who Should NOT Take MyHep All?

MyHep All is generally well-tolerated, but it is not suitable for everyone:

• People with known allergy to Sofosbuvir, Velpatasvir, or any tablet component
• Patients taking Amiodarone (heart medication) — risk of life-threatening bradycardia
• Patients taking strong inducers of P-glycoprotein or CYP2B6/CYP3A4 (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John’s Wort) — these significantly reduce drug levels and can cause treatment failure
• Pregnant women — especially if Ribavirin is part of the regimen (Ribavirin is absolutely contraindicated in pregnancy)
• Children under 6 years of age or weighing less than 17 kg — safety not established for this fixed-dose tablet
• Patients with severe renal impairment (eGFR < 30 mL/min) or on dialysis — use with caution; consult a specialist

MyHep All Drug Interactions

Because Velpatasvir is metabolized by multiple liver enzymes and is a P-glycoprotein substrate, it has important drug interactions to be aware of:

📌 This list is not exhaustive. Always provide your doctor and pharmacist with a complete medication history before starting MyHep All.

Important Precautions Before Starting MyHep All

1. Test for Hepatitis B Before Starting All patients should be screened for Hepatitis B (HBsAg, anti-HBc) before starting MyHep All. HCV treatment can suppress the immune response to HBV, triggering reactivation — which can be severe or even fatal. If HBV is detected, your doctor will manage both infections simultaneously.

2. Know Your Liver Status Understanding whether you have cirrhosis — and if so, how severe — determines your exact treatment regimen. Tests like FibroScan, FibroTest, or liver biopsy may be ordered before treatment.

3. Kidney Function While MyHep All is generally safe for patients with mild-to-moderate kidney disease, those with severe renal impairment need specialist guidance. Monitor renal function during treatment.

4. Pregnancy & Contraception MyHep All alone is not known to cause fetal harm, but if prescribed with Ribavirin, two forms of contraception are required for both partners during treatment and for 6 months after. Ribavirin is highly teratogenic.

5. No Alcohol During Treatment Alcohol directly damages the liver. Drinking during Hepatitis C treatment undermines the healing your liver needs to do. Avoid alcohol completely during the 12-week course — and ideally beyond.

6. Post-Treatment Follow-Up After completing treatment, your doctor will order an HCV RNA test at 12 weeks post-treatment to confirm SVR12. Even after achieving cure, ongoing monitoring of liver health is recommended — especially if cirrhosis was present.

MyHep All vs. Other Hepatitis C Treatments

MyHep All stands out for its pan-genotypic coverage, once-daily single-tablet convenience, and excellent affordability as a generic option — making it one of the most accessible Hepatitis C cures globally.

Frequently Asked Questions About MyHep All (Sofosbuvir & Velpatasvir)

Q: Does MyHep All cure Hepatitis C permanently? 

Yes — achieving SVR12 is considered a functional cure. Once the virus is undetectable 12 weeks post-treatment, the chance of it returning is less than 2%. Most patients are considered permanently cured.

Q: Can I take MyHep All with food? 

Yes. MyHep All can be taken with or without food. However, if you’re also taking a proton pump inhibitor (like Omeprazole), it’s best to take MyHep All with food and at least 4 hours before the PPI.

Q: Will my liver recover after treatment?

 In many cases, yes. The liver has a remarkable ability to regenerate. After clearing HCV, liver inflammation reduces significantly and early-stage fibrosis can partially or fully reverse over time. However, advanced cirrhosis may not fully reverse, though progression stops.

Q: Is MyHep All safe for elderly patients? 

Yes. No dose adjustment is required for elderly patients based on age alone. However, kidney function should be monitored, especially in older adults.

Q: Can I drink alcohol while taking MyHep All? 

It is strongly advised to avoid alcohol completely during treatment. Alcohol is toxic to the liver, and you want to give your liver every opportunity to heal during this critical 12-week window.

Final Thoughts

MyHep All (Sofosbuvir & Velpatasvir) represents one of the most significant achievements in modern medicine — a simple, once-daily tablet that can cure Hepatitis C in just 12 weeks, with cure rates approaching 99% and a side effect profile far gentler than anything that came before it.

If you have been diagnosed with chronic Hepatitis C, there has never been a better time to seek treatment. The days of painful Interferon injections, year-long treatment courses, and low cure rates are long gone. MyHep All has replaced all of that with something clean, simple, and remarkably effective.

Talk to your doctor, get tested, understand your liver status, rule out any drug interactions — and then commit to those 12 weeks. A life free from Hepatitis C is genuinely within reach.

Disclaimer:-

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified gastroenterologist or hepatologist before starting, stopping, or changing any medication, including MyHep All (Sofosbuvir & Velpatasvir).